PharmaCyte Biotech Cell Encapsulation Technology Could Re-Shape and Lead Advancements in Diabetes Treatments

BALTIMORE, October 13, 2015 /PRNewswire/ --

Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB: PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit http://www.GoldmanResearch.com.  

In the article, analyst Rob Goldman discusses how success in PharmaCyte Biotech's diabetes treatment studies alone could be worth billions of dollars and change the lives of millions since there is no cure for the disease.  

According to Goldman, "The global diabetes market for therapeutic devices and drugs is expected to reach US $114.3 billion by 2018. This figure includes current insulin injection and pump therapies used to treat Type 1 diabetes. As outlined in the article, the PMCB Cell-in-a-Box^® -based treatment system approach could potentially replace these therapies.

PharmaCyte Biotech has the exclusive worldwide rights to use Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. A recent article published in scientific journal Molecular Therapy noted that when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal. This observation illustrates that Melligen cells can reverse the diabetic condition.

However, the Melligen cells take care of only part of the problem. In order for the cells to be effective in treating humans with T1D, they must be protected from the body's immune system after introduction, which is where PMCB comes in. Therefore, the Melligen cell line, when combined with Cell-in-a-Box^® encapsulation, could ultimately become a treatment that has clear advantages over current insulin injection and pump therapies for Type 1 diabetes and potentially supplant these therapies.  

One of the next steps is to engage in vivo studies using Cell-in-a-Box^® to confirm the Melligen line's viability after encapsulation, and other parameters related to its insulin production. Upon successful completion of these Cell-in-a-Box^®/Melligen tests, the next stage would be to initiate early-phase human clinical trials, which will be watched very closely by doctors and patients alike, and put PharmaCyte Biotech atop the diabetes treatment leaderboard.

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc.  The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only.  Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit http://www.goldmanresearch.com. In 2015, Goldman Small Cap Research has been compensated by a third party in the amount of $18,000 for investment research services that includes the publication of research reports, updates, and a series of articles.

About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB - PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found at http://www.PharmaCyteBiotech.com.

Goldman Small Cap Research
Rob Goldman, Analyst
+1-410-609-7100
[email protected]

SOURCE Goldman Small Cap Research